Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME) from its SEC filings: 2025 revenue $106.0 million (+39% vs the year before), net margin -77%, free cash flow -$34.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $106.0 million |
| Revenue growth | +39% |
| Net income | -$81.1 million |
| Net margin | -76.6% |
| Free cash flow | -$34.5 million |
| Diluted EPS | $-1.08 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -91% |
| Cash | $179.4 million |
| Share count, 1 year | -6% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.